Evidence map›Paper›PMID 32945147›Full record

ArticleCancer medicine2020

Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.

Eleanor C Semmes, Erica Shen, Jennifer L Cohen, Chenan Zhang, Qingyi Wei, Jillian H Hurst, Kyle M Walsh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Eleanor C SemmesMedical Scientist Training Program, Duke University, Durham, NC, USA.ORCID 0000-0003-2595-1948
Erica ShenDivision of Neuro-epidemiology, Department of Neurosurgery, Duke University, Durham, NC, USA.
Jennifer L CohenDivision of Medical Genetics, Department of Pediatrics, Duke University, Durham, NC, USA.
Chenan ZhangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Qingyi WeiDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3845-9445
Jillian H HurstDepartment of Pediatrics, Children's Health and Discovery Institute, Duke University, Durham, NC, USA.
Kyle M WalshDepartment of Pediatrics, Children's Health and Discovery Institute, Duke University, Durham, NC, USA.ORCID 0000-0002-5879-9981
Duke University · USUniversity of California, San Francisco · US

Funding

Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
NCI NIH HHS T32 CA151022
6 · The paper itself

Abstract

backgroundNeuroblastoma is the most common pediatric solid tumor. MYCN-amplification is an important negative prognostic indicator and inherited genetic contributions to risk are incompletely understood. Genetic determinants of stature increase risk of several adult and childhood cancers, but have not been studied in neuroblastoma despite elevated neuroblastoma incidence in children with congenital overgrowth syndromes.

methodsWe investigated the association between genetic determinants of height and neuroblastoma risk in 1538 neuroblastoma cases, stratified by MYCN-amplification status, and compared to 3390 European-ancestry controls using polygenic scores for birth length (five variants), childhood height (six variants), and adult height (413 variants). We further examined the UK Biobank to evaluate the association of known neuroblastoma risk loci and stature.

resultsAn increase in the polygenic score for childhood stature, corresponding to a ~0.5 cm increase in pre-pubertal height, was associated with greater risk of MYCN-amplified neuroblastoma (OR = 1.14, P = .047). An increase in the polygenic score for adult stature, corresponding to a ~1.7 cm increase in adult height attainment, was associated with decreased risk of MYCN-amplified neuroblastoma (OR = 0.87, P = .047). These associations persisted in case-case analyses comparing MYCN-amplified to MYCN-unamplified neuroblastoma. No polygenic height scores were associated with MYCN-unamplified neuroblastoma risk. Previously identified genome-wide association study hits for neuroblastoma (N = 10) were significantly enriched for association with both childhood (P = 4.0 × 10

conclusionsGenetic propensity to taller childhood height and shorter adult height were associated with MYCN-amplified neuroblastoma risk, suggesting that biological pathways affecting growth trajectories and pubertal timing may contribute to MYCN-amplified neuroblastoma etiology.

Indexed as

AdultBody HeightCase-Control StudiesChildDatabases, GeneticGene AmplificationGenome-Wide Association StudyHaplotypesHumansInfant, NewbornNeuroblastomaN-Myc Proto-Oncogene ProteinPhenotypePolymorphism, Single NucleotideRisk FactorsMYCN protein, humanN-Myc Proto-Oncogene Proteincancer geneticsCancer Medicinecancer risk factorsepidemiologygenome-wide associationheightMYCNneuroblastomapathway analysispediatric cancerpolygenic scorestature

Identifiers

PMID32945147
PMCPMC7643638
OpenAlexW3087122197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.